1.
Schainfeld, R.M., Management of peripheral arterial disease and intermittent claudication.
J Am Board Fam Pract, 2001. 14(6): p. 443-50.
2.
Fowkes, F.G., et al., Comparison of global estimates of prevalence and risk factors for
peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet,
2013. 382(9901): p. 1329-40.
3.
Tsigkou, V., et al., Peripheral artery disease and antiplatelet treatment. Curr Opin
Pharmacol, 2018. 39: p. 43-52.
4.
Garg, P.K., et al., Physical activity during daily life and mortality in patients with peripheral
arterial disease. Circulation, 2006. 114(3): p. 242-8.
5.
Nead, K.T., et al., Walking impairment questionnaire improves mortality risk prediction
models in a high-risk cohort independent of peripheral arterial disease status. Circ
Cardiovasc Qual Outcomes, 2013. 6(3): p. 255-61.
6.
Aboyans, V., et al., 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral
Arterial Diseases, in collaboration with the European Society for Vascular Surgery
(ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral,
mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke
Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial
Diseases of the European Society of Cardiology (ESC) and of the European Society for
Vascular Surgery (ESVS). Eur Heart J, 2018. 39(9): p. 763-816.
7.
Gerhard-Herman, M.D., et al., 2016 AHA/ACC Guideline on the Management of Patients
With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the
American College of Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines. J Am Coll Cardiol, 2017. 69(11): p. 1465-1508.
8.
Biswas, M.P., et al., Exercise Training and Revascularization in the Management of
Symptomatic Peripheral Artery Disease. JACC Basic Transl Sci, 2021. 6(2): p. 174-188.
9.
Firnhaber, J.M. and C.S. Powell, Lower Extremity Peripheral Artery Disease: Diagnosis
and Treatment. Am Fam Physician, 2019. 99(6): p. 362-369.
10.
Money, S.R., et al., Effect of cilostazol on walking distances in patients with intermittent
claudication caused by peripheral vascular disease. J Vasc Surg, 1998. 27(2): p. 267-74;
discussion 274-5.
11.
Dawson, D.L., et al., A comparison of cilostazol and pentoxifylline for treating intermittent
claudication. Am J Med, 2000. 109(7): p. 523-30.
12.
Gerhard-Herman, M.D., et al., 2016 AHA/ACC Guideline on the Management of Patients
With Lower Extremity Peripheral Artery Disease: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
53
Circulation, 2017. 135(12): p. e726-e779.
13.
Inampudi, C., et al., Angiogenesis in peripheral arterial disease. Curr Opin Pharmacol,
2018. 39: p. 60-67.
14.
Duong Van Huyen, J.P., et al., Bone marrow-derived mononuclear cell therapy induces
distal angiogenesis after local injection in critical leg ischemia. Mod Pathol, 2008. 21(7):
p. 837-46.
15.
Murphy, T.P., et al., Supervised exercise versus primary stenting for claudication resulting
from aortoiliac peripheral artery disease: six-month outcomes from the claudication:
exercise versus endoluminal revascularization (CLEVER) study. Circulation, 2012.
125(1): p. 130-9.
16.
Olin, J.W., et al., Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy,
and Endovascular Options. J Am Coll Cardiol, 2016. 67(11): p. 1338-57.
17.
Watson, L., B. Ellis, and G.C. Leng, Exercise for intermittent claudication. Cochrane
Database Syst Rev, 2008(4): p. CD000990.
18.
Stewart, K.J., et al., Exercise training for claudication. N Engl J Med, 2002. 347(24): p.
1941-51.
19.
Baker, W.B., et al., Effects of exercise training on calf muscle oxygen extraction and blood
flow in patients with peripheral artery disease. J Appl Physiol (1985), 2017. 123(6): p.
1599-1609.
20.
Holloszy, J.O., Biochemical adaptations in muscle. Effects of exercise on mitochondrial
oxygen uptake and respiratory enzyme activity in skeletal muscle. J Biol Chem, 1967.
242(9): p. 2278-82.
21.
Gollnick, P.D., et al., Effect of training on enzyme activity and fiber composition of human
skeletal muscle. J Appl Physiol, 1973. 34(1): p. 107-11.
22.
Holloszy, J.O. and F.W. Booth, Biochemical adaptations to endurance exercise in muscle.
Annu Rev Physiol, 1976. 38: p. 273-91.
23.
Handschin, C. and B.M. Spiegelman, The role of exercise and PGC1alpha in
inflammation and chronic disease. Nature, 2008. 454(7203): p. 463-9.
24.
Schnyder, S. and C. Handschin, Skeletal muscle as an endocrine organ: PGC-1alpha,
myokines and exercise. Bone, 2015. 80: p. 115-125.
25.
Weihrauch, M. and C. Handschin, Pharmacological targeting of exercise adaptations in
skeletal muscle: Benefits and pitfalls. Biochem Pharmacol, 2018. 147: p. 211-220.
26.
Anderson, S.I., et al., Chronic transcutaneous electrical stimulation of calf muscles
improves functional capacity without inducing systemic inflammation in claudicants. Eur
J Vasc Endovasc Surg, 2004. 27(2): p. 201-9.
27.
Pette, D. and G. Vrbova, What does chronic electrical stimulation teach us about muscle
54
plasticity? Muscle Nerve, 1999. 22(6): p. 666-77.
28.
Theriault, R., G. Theriault, and J.A. Simoneau, Human skeletal muscle adaptation in
response to chronic low-frequency electrical stimulation. J Appl Physiol (1985), 1994.
77(4): p. 1885-9.
29.
Theriault, R., et al., Electrical stimulation-induced changes in performance and fiber type
proportion of human knee extensor muscles. Eur J Appl Physiol Occup Physiol, 1996.
74(4): p. 311-7.
30.
Sanada, F., et al., Gene therapy in peripheral artery disease. Expert Opin Biol Ther, 2015.
15(3): p. 381-90.
31.
Peeters Weem, S.M., et al., Bone Marrow derived Cell Therapy in Critical Limb Ischemia:
A Meta-analysis of Randomized Placebo Controlled Trials. Eur J Vasc Endovasc Surg,
2015. 50(6): p. 775-83.
32.
McDermott, M.M., Lower extremity manifestations of peripheral artery disease: the
pathophysiologic and functional implications of leg ischemia. Circ Res, 2015. 116(9): p.
1540-50.
33.
Hamburg, N.M. and G.J. Balady, Exercise rehabilitation in peripheral artery disease:
functional impact and mechanisms of benefits. Circulation, 2011. 123(1): p. 87-97.
34.
Thompson, P.D., et al., Exercise and physical activity in the prevention and treatment of
atherosclerotic cardiovascular disease: a statement from the Council on Clinical
Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council
on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).
Circulation, 2003. 107(24): p. 3109-16.
35.
Nagatomo, F., et al., The effects of running exercise on oxidative capacity and PGC1alpha mRNA levels in the soleus muscle of rats with metabolic syndrome. J Physiol Sci,
2012. 62(2): p. 105-14.
36.
Michelini, L.C. and J.E. Stern, Exercise-induced neuronal plasticity in central autonomic
networks: role in cardiovascular control. Exp Physiol, 2009. 94(9): p. 947-60.
37.
Taubert, M., A. Villringer, and N. Lehmann, Endurance Exercise as an "Endogenous"
Neuro-enhancement Strategy to Facilitate Motor Learning. Front Hum Neurosci, 2015. 9:
p. 692.
38.
Yan, Z., et al., Regulation of exercise-induced fiber type transformation, mitochondrial
biogenesis, and angiogenesis in skeletal muscle. J Appl Physiol (1985), 2011. 110(1): p.
264-74.
39.
Endo, K., et al., Dynamic exercise improves cognitive function in association with
increased prefrontal oxygenation. J Physiol Sci, 2013. 63(4): p. 287-98.
40.
Rockl, K.S., et al., Skeletal muscle adaptation to exercise training: AMP-activated protein
55
kinase mediates muscle fiber type shift. Diabetes, 2007. 56(8): p. 2062-9.
41.
Rockl, K.S., C.A. Witczak, and L.J. Goodyear, Signaling mechanisms in skeletal muscle:
acute responses and chronic adaptations to exercise. IUBMB Life, 2008. 60(3): p. 14553.
42.
Pette, D. and G. Vrbova, Adaptation of mammalian skeletal muscle fibers to chronic
electrical stimulation. Rev Physiol Biochem Pharmacol, 1992. 120: p. 115-202.
43.
Muhammad, M.H. and M.M. Allam, Resveratrol and/or exercise training counteract agingassociated decline of physical endurance in aged mice; targeting mitochondrial
biogenesis and function. J Physiol Sci, 2018. 68(5): p. 681-688.
44.
Atherton, P.J., et al., Selective activation of AMPK-PGC-1alpha or PKB-TSC2-mTOR
signaling can explain specific adaptive responses to endurance or resistance training-like
electrical muscle stimulation. FASEB J, 2005. 19(7): p. 786-8.
45.
Hudlicka, O., et al., Effect of long-term electrical stimulation on vascular supply and
fatigue in chronically ischemic muscles. J Appl Physiol (1985), 1994. 77(3): p. 1317-24.
46.
Brown, M.D., et al., A new model of peripheral arterial disease: sustained impairment of
nutritive
microcirculation
and
its
recovery
by
chronic
electrical
stimulation.
Microcirculation, 2005. 12(4): p. 373-81.
47.
Tang, G.L., et al., The effect of gradual or acute arterial occlusion on skeletal muscle
blood flow, arteriogenesis, and inflammation in rat hindlimb ischemia. J Vasc Surg, 2005.
41(2): p. 312-20.
48.
Egginton, S. and O. Hudlicka, Selective long-term electrical stimulation of fast glycolytic
fibres increases capillary supply but not oxidative enzyme activity in rat skeletal muscles.
Exp Physiol, 2000. 85(5): p. 567-73.
49.
Deveci, D. and S. Egginton, Differing mechanisms of cold-induced changes in capillary
supply in m. tibialis anterior of rats and hamsters. J Exp Biol, 2002. 205(Pt 6): p. 829-40.
50.
Koutakis, P., et al., Oxidative damage in the gastrocnemius of patients with peripheral
artery disease is myofiber type selective. Redox Biol, 2014. 2: p. 921-8.
51.
Regensteiner, J.G., et al., Chronic changes in skeletal muscle histology and function in
peripheral arterial disease. Circulation, 1993. 87(2): p. 413-21.
52.
Makitie, J. and H. Teravainen, Histochemical changes in striated muscle in patients with
intermittent claudication. Arch Pathol Lab Med, 1977. 101(12): p. 658-63.
53.
Gardner, A.W., et al., Prediction of claudication pain from clinical measurements obtained
at rest. Med Sci Sports Exerc, 1992. 24(2): p. 163-70.
54.
Wilson, J.M., et al., The effects of endurance, strength, and power training on muscle
fiber type shifting. J Strength Cond Res, 2012. 26(6): p. 1724-9.
55.
Dreibati, B., et al., Influence of electrical stimulation frequency on skeletal muscle force
56
and fatigue. Ann Phys Rehabil Med, 2010. 53(4): p. 266-71, 271-7.
56.
Maillefert, J.F., et al., Effects of low-frequency electrical stimulation of quadriceps and calf
muscles in patients with chronic heart failure. J Cardiopulm Rehabil, 1998. 18(4): p. 27782.
57.
Hellsten, Y. and M. Nyberg, Cardiovascular Adaptations to Exercise Training. Compr
Physiol, 2015. 6(1): p. 1-32.
58.
Mann, N. and A. Rosenzweig, Can exercise teach us how to treat heart disease?
Circulation, 2012. 126(22): p. 2625-35.
59.
Zavorsky, G.S., Evidence and possible mechanisms of altered maximum heart rate with
endurance training and tapering. Sports Med, 2000. 29(1): p. 13-26.
60.
Kang, J.H. and I.H. Hyong, The influence of neuromuscular electrical stimulation on the
heart rate variability in healthy subjects. J Phys Ther Sci, 2014. 26(5): p. 633-5.
61.
Barauna, V.G., et al., Cardiovascular adaptations in rats submitted to a resistance-training
model. Clin Exp Pharmacol Physiol, 2005. 32(4): p. 249-54.
62.
Fakhry, F., et al., Endovascular Revascularization and Supervised Exercise for Peripheral
Artery Disease and Intermittent Claudication: A Randomized Clinical Trial. JAMA, 2015.
314(18): p. 1936-44.
63.
Sorlie, D. and K. Myhre, Effects of physical training in intermittent claudication. Scand J
Clin Lab Invest, 1978. 38(3): p. 217-22.
64.
Parmenter, B.J., et al., A systematic review of randomized controlled trials: Walking
versus alternative exercise prescription as treatment for intermittent claudication.
Atherosclerosis, 2011. 218(1): p. 1-12.
65.
Englund, E.K., et al., Multiparametric assessment of vascular function in peripheral artery
disease: dynamic measurement of skeletal muscle perfusion, blood-oxygen-level
dependent signal, and venous oxygen saturation. Circ Cardiovasc Imaging, 2015. 8(4).
66.
Sorlie, D. and K. Myhre, Lower leg blood flow in intermittent claudication. Scand J Clin
Lab Invest, 1978. 38(2): p. 171-9.
67.
Alpert, J.S., O.A. Larsen, and N.A. Lassen, Exercise and intermittent claudication. Blood
flow in the calf muscle during walking studied by the xenon-133 clearance method.
Circulation, 1969. 39(3): p. 353-9.
68.
Harwood, A.E., et al., A Review of the Potential Local Mechanisms by Which Exercise
Improves Functional Outcomes in Intermittent Claudication. Ann Vasc Surg, 2016. 30: p.
312-20.
69.
White, S.H., et al., Walking performance is positively correlated to calf muscle fiber size
in peripheral artery disease subjects, but fibers show aberrant mitophagy: an
observational study. J Transl Med, 2016. 14(1): p. 284.
57
70.
Holloszy, J.O. and E.F. Coyle, Adaptations of skeletal muscle to endurance exercise and
their metabolic consequences. J Appl Physiol Respir Environ Exerc Physiol, 1984. 56(4):
p. 831-8.
71.
Henique, C., et al., Increasing mitochondrial muscle fatty acid oxidation induces skeletal
muscle remodeling toward an oxidative phenotype. FASEB J, 2015. 29(6): p. 2473-83.
72.
Rangwala, S.M., et al., Estrogen-related receptor gamma is a key regulator of muscle
mitochondrial activity and oxidative capacity. J Biol Chem, 2010. 285(29): p. 22619-29.
73.
An, D., et al., Overexpression of TRB3 in muscle alters muscle fiber type and improves
exercise capacity in mice. Am J Physiol Regul Integr Comp Physiol, 2014. 306(12): p.
R925-33.
74.
Handschin, C., et al., Skeletal muscle fiber-type switching, exercise intolerance, and
myopathy in PGC-1alpha muscle-specific knock-out animals. J Biol Chem, 2007.
282(41): p. 30014-21.
75.
Waters, R.E., et al., Voluntary running induces fiber type-specific angiogenesis in mouse
skeletal muscle. Am J Physiol Cell Physiol, 2004. 287(5): p. C1342-8.
76.
Correction to: 2016 AHA/ACC Guideline on the Management of Patients With Lower
Extremity Peripheral Artery Disease: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation, 2017. 135(12): p. e791-e792.
77.
Treat-Jacobson, D., et al., Implementation of Supervised Exercise Therapy for Patients
With Symptomatic Peripheral Artery Disease: A Science Advisory From the American
Heart Association. Circulation, 2019. 140(13): p. e700-e710.
78.
Shiragaki-Ogitani, M., et al., Neuromuscular stimulation ameliorates ischemia-induced
walking impairment in the rat claudication model. J Physiol Sci, 2019.
79.
Lamers, D., et al., Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity
to the metabolic syndrome. Diabetes, 2011. 60(7): p. 1917-25.
80.
Qi, X., et al., Combination of exendin-4 and DPP-4 silencing promoted angiogenesis of
human coronary artery endothelial cells via activation of PI3K/Akt pathway. Pak J Pharm
Sci, 2017. 30(2(Suppl.)): p. 555-560.
81.
Wu, C., et al., Dipeptidyl peptidase4 inhibitor sitagliptin prevents high glucoseinduced
apoptosis via activation of AMPactivated protein kinase in endothelial cells. Mol Med Rep,
2017. 15(6): p. 4346-4351.
82.
Nagamine, A., et al., The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in
human umbilical vein endothelial cells. J Pharmacol Sci, 2017. 133(1): p. 42-48.
83.
Chang, C.C., et al., Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and
Lower Extremity Amputation Risk in Diabetic Patients. Am J Med, 2017. 130(3): p. 348-
58
355.
84.
Sakamoto, K., et al., The nephroblastoma overexpressed gene (NOV/ccn3) protein
associates with Notch1 extracellular domain and inhibits myoblast differentiation via
Notch signaling pathway. J Biol Chem, 2002. 277(33): p. 29399-405.
85.
Lin, C.G., et al., CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family.
J Biol Chem, 2003. 278(26): p. 24200-8.
86.
Heath, E., et al., Abnormal skeletal and cardiac development, cardiomyopathy, muscle
atrophy and cataracts in mice with a targeted disruption of the Nov (Ccn3) gene. BMC
Dev Biol, 2008. 8: p. 18.
87.
Wolf, N., et al., Regulation of the matricellular proteins CYR61 (CCN1) and NOV (CCN3)
by hypoxia-inducible factor-1{alpha} and transforming-growth factor-{beta}3 in the human
trophoblast. Endocrinology, 2010. 151(6): p. 2835-45.
88.
Calhabeu, F., et al., NOV/CCN3 impairs muscle cell commitment and differentiation. Exp
Cell Res, 2006. 312(10): p. 1876-89.
89.
Lin, C.G., et al., Integrin-dependent functions of the angiogenic inducer NOV (CCN3):
implication in wound healing. J Biol Chem, 2005. 280(9): p. 8229-37.
90.
Stichtenoth, D.O., et al., Microsomal prostaglandin E synthase is regulated by
proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J
Immunol, 2001. 167(1): p. 469-74.
91.
Trebino, C.E., et al., Impaired inflammatory and pain responses in mice lacking an
inducible prostaglandin E synthase. Proc Natl Acad Sci U S A, 2003. 100(15): p. 9044-9.
92.
Wang, M., et al., Deletion of microsomal prostaglandin E synthase-1 augments
prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A, 2006. 103(39): p.
14507-12.
93.
Ikeda-Matsuo, Y., et al., Microsomal prostaglandin E synthase-1 is a critical factor of
stroke-reperfusion injury. Proc Natl Acad Sci U S A, 2006. 103(31): p. 11790-5.
94.
Leclerc, P., et al., Characterization of a human and murine mPGES-1 inhibitor and
comparison to mPGES-1 genetic deletion in mouse models of inflammation.
Prostaglandins Other Lipid Mediat, 2013. 107: p. 26-34.
95.
Leclerc, P., et al., Characterization of a new mPGES-1 inhibitor in rat models of
inflammation. Prostaglandins Other Lipid Mediat, 2013. 102-103: p. 1-12.
96.
Mo, C., et al., Prostaglandin E2: from clinical applications to its potential role in bonemuscle crosstalk and myogenic differentiation. Recent Pat Biotechnol, 2012. 6(3): p. 2239.
97.
Mo, C., et al., Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via
EP4 receptor activation. Cell Cycle, 2015. 14(10): p. 1507-16.
59
98.
Chen, D., et al., E-Prostanoid 3 Receptor Mediates Sprouting Angiogenesis Through
Suppression of the Protein Kinase A/beta-Catenin/Notch Pathway. Arterioscler Thromb
Vasc Biol, 2017. 37(5): p. 856-866.
99.
Zhuang, Z.W., et al., Challenging the surgical rodent hindlimb ischemia model with the
miniinterventional technique. J Vasc Interv Radiol, 2011. 22(10): p. 1437-46.
100.
Barker, G.A., et al., Walking performance, oxygen uptake kinetics and resting muscle
pyruvate dehydrogenase complex activity in peripheral arterial disease. Clin Sci (Lond),
2004. 106(3): p. 241-9.
101.
Steiner, J.L., et al., Adrenal stress hormone action in skeletal muscle during exercise
training: An old dog with new tricks? Acta Physiol (Oxf), 2021. 231(1): p. e13522.
102.
Boschmann, M., et al., Dipeptidyl-peptidase-IV inhibition augments postprandial lipid
mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab, 2009.
94(3): p. 846-52.
103.
Takada, S., et al., Dipeptidyl peptidase-4 inhibitor improved exercise capacity and
mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide1 receptor signalling. Cardiovasc Res, 2016. 111(4): p. 338-47.
60
...
論文の公開元へ
